Latest revenue
$706.6M
as of 2026-03-31
Latest net income
$123.9M
as of 2026-03-31
Net margin
17.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $12.36B
- Enterprise value
- $12.36B
- P/E (trailing)
- 27.4×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $628.92
- 52-wk low
- $291.28
- Beta
- —
- Shares out
- 28.6M
5-year trend
What this company does
Item 1. Business Overview We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers. We…
AI summary unavailable — showing raw filing excerpt
Generated from MEDP's filing dated 2026-02-10
Key risks
Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with the other information included in this report. The occurrence of any of the following risks may materially and adversely affect our business, financial condition, results of operations and future prospects. In these circumstances, the market price of our common stock could decline. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations. Risk Factor Summary The following summarizes the most material risks…
AI summary unavailable — showing raw filing excerpt
Generated from MEDP's filing dated 2026-02-10
Profitability
Operating margin
21.1%
0.2%Net margin
17.8%
7.0%Return on equity
98.3%
100.6%Return on assets
22.8%
18.6%Leverage
Debt / equity
3.30×
113.8%Debt / assets
76.8%
26.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $706.6M | +26.5% | $123.9M | +8.1% | 17.5% |
Q4 2025 2025-12-31 | $708.5M | +32.0% | $135.1M | +15.5% | 19.1% |
Q3 2025 2025-09-30 | $659.9M | +23.7% | $111.1M | +15.3% | 16.8% |
Q2 2025 2025-06-30 | $603.3M | +14.2% | $90.3M | +2.2% | 15.0% |
Q1 2025 2025-03-31 | $558.6M | +9.3% | $114.6M | +11.7% | 20.5% |
Q4 2024 2024-12-31 | $536.6M | — | $117.0M | — | 21.8% |
Q3 2024 2024-09-30 | $533.3M | +8.3% | $96.4M | +36.7% | 18.1% |
Q2 2024 2024-06-30 | $528.1M | +14.6% | $88.4M | +44.7% | 16.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Commercial Physical & Biological Research · SIC 8731
Your notes
Keep private notes on MEDP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$325.9M
Net activity
−$325.9M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns MEDP
Institutional value
$6.26B
Total shares held
14.1M
Distinct holders
497
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2.5M | $1.19B | — | New |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.1M | $538.6M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.0M | $485.5M | — | New |
| 4 | WASATCH ADVISORS LP | 773.9K | $371.6M | — | New |
| 5 | Invesco Ltd. | 577.6K | $277.3M | — | New |
| 6 | BAILLIE GIFFORD & CO | 503.2K | $241.6M | — | New |
| 7 | Mawer Investment Management Ltd. | 446.1K | $214.2M | — | New |
| 8 | DIMENSIONAL FUND ADVISORS LP | 348.5K | $167.3M | — | New |
| 9 | UBS Group AG | 340.4K | $163.5M | — | New |
| 10 | Madison Asset Management, LLC | 262.3K | $126.0M | — | New |
| 11 | RIVERBRIDGE PARTNERS LLC | 237.4K | $114.0M | — | New |
| 12 | Vulcan Value Partners, LLC | 203.1K | $97.5M | — | New |
| 13 | FRANKLIN RESOURCES INC | 201.7K | $96.9M | — | New |
| 14 | Clearbridge Investments, LLC | 176.0K | $84.5M | — | New |
| 15 | Stephens Investment Management Group LLC | 162.8K | $78.2M | — | New |
| 16 | Bank of New York Mellon Corp | 159.2K | $76.5M | — | New |
| 17 | JPMORGAN CHASE & CO | 153.6K | $70.7M | — | New |
| 18 | VANGUARD FIDUCIARY TRUST CO | 142.5K | $68.4M | — | New |
| 19 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 140.8K | $67.6M | — | New |
| 20 | Boston Trust Walden Corp | 140.6K | $67.5M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once MEDP's latest filing finishes processing.